HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096 · cited 1×
“iPrEx [14] MSM c 2499 TDF/FTC 44 15–63 51 92 40–99”
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256 · cited 2×
“TDF/FTC combination PrEP showed a more favorable efficacy profile compared with TDF monotherapy PrEP in current studies [11, 13].”
ResultAntiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996 · cited 2×
“TDF 2 [20] Heterosexual c 1200 TDF/FTC 62 22–83 80 85 NS”
Preexposure Prophylaxis for HIV Infection among African Women
Van Damme, L., Corneli, A., Ahmed, K., Agot, K., Lombaard, J., Kapiga, S., Malahleha, M., Owino, F., Manongi, R., Onyango, J., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202614 · Cited by 1,603 · cited 1×
“Fem-PrEP [12] Heterosexual women c 1951 TDF/FTC 6 −52 to 41 <30 NR –”
Choopanya, K., Martin, M., Suntharasamai, P., Sangkum, U., Mock, P. A., Leethochawalit, M., Chiamwongpaet, S., Kitisin, P., Natrujirote, P., Kittimunkong, S., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61127-7 · Cited by 1,463 · cited 2×
“Bangkok Tenofovir Study [17] IVDA c 2413 TDF 49 10–72 67 74 2–91”
BackgroundTenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402269 · Cited by 1,296 · cited 2×
“Voice [13] Heterosexual women c 5029 TDF/FTC 6.”
BackgroundResultAnderson, P. L., Glidden, D. V., Liu, A., Buchbinder, S., Lama, J. R., Guanira, J. V., McMahan, V., Bushman, L. R., Casapía, M., Montoya-Herrera, O., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004006 · Cited by 1,020 · cited 2×
“Efficacy raised to 92 % (95 % CI 40–99) in subjects with detectable tenofovir (TVF) plasma levels, indicating higher adherence to the study drug [18].”
BackgroundPatterson, K. B., Prince, H. A., Kraft, E., Jenkins, A. J., Shaheen, N. J., Rooney, J. F., Cohen, M. S., & Kashuba, A. D. M. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003174 · Cited by 355 · cited 2×
“The reasons for the highly different efficacy of PrEP in MSM, men and women might be associated with adherence, different tenofovir (TFV) vaginal and anal mucosa penetration and potentially cultural settings [10].”
BackgroundGarcía-Lerma, J. G., Otten, R. A., Qari, S. H., Jackson, E., Cong, M.-E., Masciotra, S., Luo, W., Kim, C., Adams, D. R., Monsour, M., et al. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050028 · Cited by 350 · cited 2×
“Also, animal models demonstrated lower risk reduction of HIV transmission in vaginal intercourse compared to rectal intercourse [9].”
BackgroundHIV treatment as prevention and HPTN 052
Cohen, M. S., McCauley, M., & Gamble, T. R. (2012) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32834f5cf2 · Cited by 301 · cited 1×
“Potent and modern ART drugs and their combinations facilitate durable HIV suppression below the lower limit of quantification (LLOQ), which significantly reduces HIV transmission risk [2].”
Background
Cited by
Bekker, L.-G., Alleyne, G., Baral, S., Cepeda, J., Daskalakis, D., Dowdy, D., Dybul, M., Eholie, S., Esom, K., Garnett, G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31070-5 · Cited by 763
Self-citationPhillips, M. A., Burrows, J. N., Manyando, C., van Huijsduijnen, R. H., Van Voorhis, W. C., & Wells, T. N. C. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.50 · Cited by 649
New developments in anti-malarial target candidate and product profiles
Burrows, J. N., Duparc, S., Gutteridge, W. E., Hooft van Huijsduijnen, R., Kaszubska, W., Macintyre, F., Mazzuri, S., Möhrle, J. J., & Wells, T. N. C. (2017) · Malaria Journal · doi:10.1186/s12936-016-1675-x · Cited by 520
Parsons, J. T., Rendina, H. J., Lassiter, J. M., Whitfield, T. H. F., Starks, T. J., & Grov, C. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001251 · Cited by 298
Metadata
- Authors
- Spinner, C. D., Boesecke, C., Zink, A., Jessen, H., Stellbrink, H.-J., Rockstroh, J. K., & Esser, S.
- Venue
- Infection
- Published
- 2015-10-15
- Volume
- 44
- Issue
- 2
- Pages
- 151-158
- ISSN
- 0300-8126 (ISSN-L)
- 1439-0973
- OpenAlex
- W2138391170
- Cited by
- 241
- References
- 21
- FWCI
- 13.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.